Guest Editor(s)

• Maurizia Rossana Brunetto, MD

  Director of the Integrated Department of Medical Specialties and of the Hepatology Unit of the Pisa University Hospital, Pisa, Italy. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

  Website | E-mail

Special Issue Introduction

New challenging issues are prompting a paradigmatic change in surveillance, early diagnosis, therapy decision making and outcome monitoring of hepatocellular carcinoma (HCC).
In the last decades, the epidemiologic features (age at onset, etiology of the underlying chronic liver disease, and comorbidities) of HCC have consistently changed. Overall, the risk of HCC development in patients with chronic viral hepatitis appears to be reduced by the new antiviral therapies, but the individual risk remains to be defined according to host and liver disease factors. Furthermore, the new therapeutic options for HCC are challenging the criteria to stage and manage the patients with HCC. New biomarkers have been identified by genetic, immune-metric, molecular biology (microRNA profiling by qPCR and NGS) and immune-histo-chemistry techniques and their kinetics are studied both in vitro, transgenic mouse models and in patients. In this special issue of Hepatoma Research, we will discuss as all these new achievements prompt new diagnostic and monitoring algorithms tailored according to the different prototypes of patients at risk or with HCC.

Submission Deadline

15 Jul 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/HR/?IssueId=615
Submission Deadline: 15 Jul 2021
Contacts: Victoria Lee, Assistant Editor, editor_Victoria@hrjournal.net